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Abstract
Background and purpose: After the failure of first-line treatment, the clinical prognosis in head and neck cancer
(HNSCC) deteriorates. Effective therapeutic strategies are limited due to the toxicity of previous treatments and the
diminished tolerance of surrounding normal tissue. This study demonstrates a promising second-line regimen, with
function preserving surgical tumor debulking, followed by a combination of postoperative interstitial brachytherapy
and a simultaneous protocol of cetuximab and taxol.
Patients and methods: From January 2006 to May 2013, 197 patients with HNSCC were treated with brachytherapy
at the University Hospital Schleswig-Holstein Campus Lübeck, including 94 patients due to recurrent cancer. Within
these, 18 patients were referred to our clinic because of early progressive disease following first- or second-line
treatment failure. They received the new palliative regimen. A matched-pair analysis including recurrent tumor
stage, status of resection margins, tissue invasion and previous therapy was performed to evaluate this treatment
retrospectively. Overall survival (OS), disease-free survival (DFS), functional outcome and treatment toxicity was
analyzed on the basis of medical records and follow-up data.
Results: DFS and OS of the study group were 8.7 and 14.8 months. Whereas, DFS and OS of the control group,
treated only by function preserving tumor debulking and brachytherapy, was 3.9 and 6.1 months respectively.
This demonstrates a positive trend through the additional use of the cetuximab-taxane protocol. Furthermore, no
increase of therapy induced toxicities was displayed.
Conclusion: Pre-treated patients with a further relapse benefit from the ‘cetuximab-taxane recurrency scheme’. It
seems to be a valuable complement to interdisciplinary and multimodal tumor therapy, which improves OS and
results in acceptable toxicity.
Keywords: Brachytherapy, Cetuximab, HNSCC, Paclitaxel, Recurrent disease, Second-line therapy
Full text article
Background and purpose
Treatment options for locally recurrent or persistent
head and neck squamous cell carcinoma (HNSCC) are
limited. Depending on initial therapy and extent of the
disease, treatment with curative intent, e.g. salvage
surgery or further radiation, is occasionally feasible.
However, in most cases recurrent disease is incurable
and treated with a palliative approach [1].
Reported studies of re-irradiation with concurrent
chemotherapy show high rates of locoregional control (LC)
(25-30 %) and improved overall survival (OS) (10-30 %
at 2 years), dependent on patient selection and treat-
ment regimen. But in comparison with studies using
chemotherapy alone, they demonstrate substantial tox-
icity (grade III-IV toxicities up to 40 % and mortality
up to 10 %) [2–5].
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Single-agent platinum chemotherapy stays the common
standard for locally advanced recurrences. The response
rate (RR), meaning the percentage of patients whose can-
cer shows a partial or complete tumor response, is esti-
mated at 15 to 30 %. Disease-free survival (DFS) averages
at 3 to 5 months and mean OS at 5 to 7 months [1, 6].
Aggressive multi-agent platinum combinations demon-
strate enhanced RR up to 40 %. However, mean OS
remains low with an average of 9 months [7, 8].
If the tumor progresses under first-line treatment or
recurs again after initial complete response (first-line
failure), the prognosis is even worse. RR to further
chemotherapy decreases to 3 % and OS is about
3.5 months [1]. The sole treatment options are palliative
chemotherapy, targeted therapy in the framework of
clinical trials and best supportive care [9]. Recom-
mended treatment strategies are single agent chemother-
apy with taxane, platinum derivate, methotrexate or
fluorouracil [10].
These patients are often debilitated and less able to
tolerate further aggressive treatment. So the indication
for additional second-line therapy has to be very strin-
gent. Particular attention has to be paid to the side effect
profile. Here a promising treatment regimen is reported
and analyzed, containing function preserving surgical
debulking, postoperative interstitial brachytherapy (BT)
and a simultaneous protocol of cetuximab and
paclitaxel.
Patients and methods
From January 2006 to May 2013, we retrospectively
reviewed 94 patients with recurrent head and neck can-
cer treated with postoperative interstitial high-dose-rate
brachytherapy (HDR-BT) at the University Hospital
Schleswig-Holstein Campus Lübeck. The study group,
who was treated with our new multimodal therapy
scheme, had developed progressive disease under or
within a short time after first- or second-line therapy.
Palliative treatment was indicated in patients with ad-
vanced locoregional disease, failing response to (radio)-
chemotherapy or exhausted radiation dose.
We included consecutive patients with histologically
confirmed recurrent cancer without evidence of distant
metastases and whose tumor was feasible to treat
with BT. All patients had adequate renal, liver and
hematological functions and were in eligible general con-
dition, without concomitant malignancies or serious ill-
ness. Thus patients included were suitable for general
anesthesia. Patients with known incompatibilities, of more
than grade III towards cetuximab or taxol, were excluded.
The decision towards the new scheme as an individual
treatment was made in our interdisciplinary tumor board
and discussed intensively with the patient. Informed
consent was taken for this individual treatment plan.
Chemotherapy
The ‘Cetuximab-Taxane Recurrency Scheme’ is based on
the findings of Bonners Extreme trial. Bonner et al.
reached a significant increase in LC and OS in locally
advanced HNSCC by adding cetuximab to radiation
[11]. Especially in platinum-refractory or -resistant dis-
ease, it seems to be a favorable option [12]. Vermorken
et al. confirmed these findings in recurrent HNSCC by
adding cetuximab to chemoradiation [13]. The guide-
lines of the National Comprehensive Cancer Network
(NCCN) included cetuximab into standard regimes of
locally advanced or recurrent head and neck cancer in
2011 (http://oralcancerfoundation.org/treatment/pdf/hea
d-and-neck.pdf ). We applied cetuximab according to
Shin et al. to reach sufficient saturation in the tumor tis-
sue [14]. Starting with a loading dose of 400 mg/m2, one
week before tumor resection and implantation of the ra-
diation catheters, cetuximab was applied with a dose of
200 mg/m2 once a week thereafter (Fig. 1).
Paclitaxel was administered only during fractionated
radiation. Taxanes have been studied in combination
with chemotherapy regimens. By adding docetaxel to
cisplatin fluorouracil (PF) induction chemotherapy RR
and OS were improved by showing a favorable toxicity
profile [15, 16]. Particularly higher RRs between 20 and
43 % were reported [6]. In our regimen, taxol was given
every three days during BT to achieve higher radiation
sensitivity. The dosage of 25 mg/m2 was less than in
other tumor protocols e.g. breast cancer.
To prevent anaphylaxis, chemoradiation was applied
in combination with prednisolon 250 mg (2 h before),
Fig. 1 The cetuximab-taxane recurrency scheme. Shows a sketch of the cetuximab-taxan recurrency scheme and its time line. The regimen
consists of operative debulking, postoperative brachytherapy and the simultaneous use of cetuximab and taxol. Brachytherapy was applied
with a single dose of 2.5 Gy twice daily to a total dose of average 27.0 Gy
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clemastin 2.68 mg and ranitidin 50 mg (1 h before). In
addition, antibiotics and calcium were administered
prophylactically to reduce perioperative infection and
radiation damage.
Surgery and BT-catheter placement
The tumor resection, reconstruction and one-step BT-
catheter placement were all applied interdisciplinary by
an experienced head and neck surgeon, under the sur-
veillance of a BT expert.
Brachytherapy
For BT treatment planning purposes, thin slice com-
puter tomography imaging was performed to control
catheter placement and to create a 3D model of the im-
plant. An individual optimized dose distribution to the
target volume was calculated respecting a possible previ-
ous or adjuvant tissue radiation dose. Hot and cold spots
were set according to biological needs: to areas of re-
sidual macroscopic tumor we applied higher local doses
(up to 200 % of the reference isodose) and organs at risk
were receiving less than the reference dose (Fig. 2).
BT was processed hypofractionated accelerated (unit
dose 2.5 Gy) twice a day, with a minimum time interval
of at least 6 hours between both fractions. Iridium-192
was used as the radiation source (370 GBq nominal ac-
tivity) delivered with the Flexitron® (Elekta) afterloading
machine.
Early and late toxicities
Documentation of early toxicities was based on the
modified CTC (common toxicity criteria) -classification
of the German Cancer Society [17]. Late toxicities were
classified by LENT (Late Effects Normal Tissue)-
SOMA-classification of the National Cancer Institute
[18]. All patients were followed up regularly, in both
departments of otorhinolaryngology and brachytherapy.
Statistics and analysis
For analysis three groups were compiled: the total group
(n = 94), the study group (n = 18) receiving the
cetuximab-taxane recurrency scheme and the matched
pair control group (n = 18).
In advance, appropriate variables had to be found to
create a control group with comparable prognosis.
Within the total group DFS was associated with previous
radiation (p = 0.004), tumor size (p = 0.025), UICC stage
(p = 0.025), tissue invasion as lymphangiosis carcinoma-
tosa and extracapsular spread (p = 0.001). OS was corre-
lated with DFS (p = 0.001), T stage (p = 0.038) and
lymphangiosis carcinomatosa (p = 0.012).
Brockstein proposes T stage, N stage and histological
differentiation to be the critical factors to affect DFS or
OS, whereas Vermorken considers tumor cell differen-
tiation, ECOG performance score, weight loss, location
of the primary tumor and prior radiotherapy to be
essential [6, 19].
Fig. 2 Dose distribution. Illustrates a thin slice computer tomography based 3D model of the implant, with optimized individual dose distribution
to the target volume (V100 = within the red isodose). Hot (V150 = within the blue isodose) and cold (V50 = within the yellow isodose) spots were
set according to biological needs: to areas of residual macroscopic tumor we applied higher local doses and organs at risk received less than the
reference dose
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Based on this information, we created the control
group by matched-pair analysis according to recurrent
tumor stage, location of primary tumor, resection margin
status, extend of tissue invasion and previous radiation.
We proved congruence and relevant differences by chi-
square test and Mann–Whitney U test.
To evaluate our regimen, study group, matched pair
control group and total group were compared by OS,
DFS, functional outcome and treatment toxicity. A
Kaplan-Meier estimator was used to analyze the data
statistically. Considering the matching process we also
used McNemar’s test and a pared sample t-test to com-
pare OS and DFS of the study group and the control
group. In a subgroup analysis we proved the impact of
further prognostic factors to our data. Statistics were cal-
culated using IBM SPSS Statistics 21, supported by our
department of statistics and biometrics.
Results
Patient and tumor characteristics
All patient and tumor characteristics are summarized in
Table 1. A total of 18 patients, 12 men and 6 women, at
a median age of 48.0 (range 45–68) were enrolled in the
treatment arm. Twelve (66.7 %) patients suffered from
advanced recurrent disease (UICC stage III-IV), due to a
higher T-stage (55.6 %) or advanced nodal disease (N1-
N2 16.7 %, N3 11.1 %). Five (27.8 %) patients with local
disease (UICC stage I-II) were treated for lymphangiosis
carcinomatosa, vessel infiltration, perineural infiltration
or positive resection margins.
Seventeen (94 %) patients were treated with surgery.
One of the patients within the treatment group re-
fused tumor reduction. In 4 (22.2 %) patients we
achieved a microscopically margin-negative resection
(R0). In 10 (55.6 %) patients microscopic tumor mass
remained (R1). However, in 3 (16.7 %) patients only
debulking of the tumor mass (R2) was feasible. Fourteen
(77.7 %) patients had surgical resection at the primary site
and 3 (16.7 %) patients received neck dissection only. In 8
(44.4 %) cases plastic reconstruction was necessary (4 ped-
icled muscle, 1 microvascular, 3 random pattern flap).
15 patients (83.3 %) were previously radiated by exter-
nal beam radiation with an average of 68.1 Gy (range
50–105). To exhaust treatment modalities, 4 (22.2 %) pa-
tients underwent adjuvant external beam radiation
(EBRT) with a unit dose of 2.0 Gy (range 1.8-2.0) in 25.8
fractions (range 25–28), to a total dose of 50.1 Gy. Two
patients received further adjuvant chemotherapy.
BT was applied for 7.1 days (range 4–9) with a fraction
dose of 2.5 Gy in mean 10.6 fractions (range 6–14), to a
mean total dose of 27.0 Gy (range 15–35). On average
we used five radiation catheters (range 3–11), using the
Paris system geometric rules for implantation.
The radiated clinical target volume (V100) was on aver-
age 61.9 ml (range 22.3-149.5). We achieved a homoge-
neous radiation field, with a mean 150-isodose surface
(V150) of 23.1 ml (range 7.1-55.2). The non-uniformity
ratio (DNR), the quotient of V100 and V150, was 0.35
(range 0.28-0.46).
The control group showed similar features regarding
tumor localization, TNM and UICC stage, tissue invasion
and resection margins. Furthermore adjuvant treatment
(besides the cetuximab-taxane regimen), function preserv-
ing tumor debulking and brachytherapy, between the
study group and the matched pair control group corre-
sponded (Table 2). Due to the inclusion criteria significant
differences in previous recurrence free survival (p = 0,003)
and age at onset of recurrence disease (p = 0,006) were de-
tected. Though not significant, similar distribution in
tumor grading was not reached as well.
Disease free survival and overall survival
Average DFS and OS of the matched pair group, treated
by debulking and brachytherapy alone, were 4.0 months
(range 0.3-25.6) and 6.2 months (range 0.5-25.6) respect-
ively. The 1- and 2-year OS rates were 68 % and 58 %,
respectively, the DFS rates were 17 % each. Whereas,
DFS and OS of the study group improved at 8.7 months
(range 0.5-42.9) and 14.9 months (range 0.5-42.9) re-
spectively. The 1- and 2-year OS rates were 85 % and
65 %, respectively, the DFS rates were 32 % and 24 %, re-
spectively. Thus, DFS was enhanced by approximately
4.7 months (p = 0.13) and OS by approximately
8.7 months (p = 0.023) (Fig. 3a-b). Survival benefit
reached significance in the paired sample t-test.
In detail, in the study group 11 (61.1 %) patients devel-
oped tumor recurrence following the treatment. Seven
(38.9 %) patients survived with recurrent disease. Four
(22.2 %) patients died of the tumor disease. In the
matched pair group 6 (33.3 %) patients developed
another relapse after treatment. Four (22.2 %) patients
survived with recurrent disease. Two (11.1 %) patients
died of the tumor, one patient due to another disease.
Although more patients developed recurrence in the
study group, the time to re-recurrence was prolonged.
The mean follow-up was 13.4 months (range 0.1-72.9).
Early and late toxicities
Early complications like lymph edema, skin reaction, muco-
sitis or wound healing disturbances were observed in 8 pa-
tients of the study group. In most cases they were less
severe (grade I-II 33.3 %, grade III 11.1 %). We recorded
specific acute toxicities of the cetuximab-taxane protocol,
like acneiform rush (11.1 %), hypersensitivity reaction
(5.5 %) or myelosuppression e.g. neutropenia (5.6 %), but
no postoperative bleeding or peripheral neuropathy.
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Late complications like fibrosis, persistent edema
or wound healing disturbances occurred in 5 (27.7 %)
patients (grade I-II 22.2 %, grade III 5.6 %). Four
(22.2 %) patients suffered from persistent dysphagia after
treatment.
Compared to the matched pair group, there was no
evident increase of therapy induced acute or late toxic-
ities more than grade III. However, mild wound healing
disturbances were detected more often in the treatment
group (Table 3).
Table 1 Patient and tumor characteristics
Total group (n = 94) Study group (n = 18) Control group (n = 18) p-values*
n % value (range) n % value (range) n % value (range)
Age < 60 years 36 38.3 13 72.2 5 27.8
Age≥ 60 years 58 61.7 5 27.8 13 72.2
Age at onset of recurrence disease (years) 62.0 (53–71) 48.0 (45–68) 66.5 (57–73) (0.006)
Time to first recurrence < 3 months 10 10.3 9 50.0 0 0
Time to first recurrence≥ 3 months 81 83.5 6 33.3 18 100
Previous recurrence free survival (months) 24.0 (10–73) 2.3 (2–8) 38.1 (18–99) (0.003)
First recurrence 49 52.1 9 50.0 7 38.9
Several recurrences 45 47.9 9 50.0 11 61.1
Previous treatment Operation 72 76.6 12 66.7 13 72.2 (0.177)
Chemotherapy 25 26.1 6 33.1 8 44.0 (0.978)
Radiotherapy 63 67.0 15 83.3 17 94.4 (0.584)
Previous total radiation dose (Gy) 64.2 (33–105) 68.1 (50–105) 66.2 (59–77) (0.696)
rTNM-stage T1-T2 38 40.4 5 27.8 7 38.9 (0.812)
T3-T4 45 47.9 10 55.6 9 50.0
Tx 9 9.6 3 16.7 2 11.1
N0 67 71.3 13 72.2 12 66.7 (1.000)
N1-N2 21 22.4 3 16.7 4 22.2
N3 3 3.2 2 11.1 1 5.6
UICC-stage Stage I-II 31 33.0 6 33.3 5 27.8 (1.000)
Stage III-IV 63 67.0 12 66.7 13 72.2
Histology SCC 75 79.8 17 94.4 15 83.3 (0.735)
Other 19 20.2 1 5.6 3 16.7
Grading Low Grade (G1-G2) 50 53.2 12 66.7 7 38.9 (0.156)
High Grade (G3-G4) 41 43.6 6 33.3 11 61.1
Localization Oral cavity 24 25.5 7 38.9 4 22.2 (0.308)
Oro-, nasopharynx 26 27.7 5 27.8 9 50.0
Hypopharynx, larynx 6 6.4 2 11.1 1 5.6
Lymph node 8 8.5 3 16.7 2 11.1
Other 30 31.9 1 5.6 2 11.1
Resection margins R0 37 39.4 4 22.2 6 33.3 (0.766)
R1 32 34.0 10 55.6 5 27.8
R2 11 11.7 3 16.7 4 22.2
Rx (unsure) 6 6.4 1 5.6 - -
No debulking 8 8.5 1 5.6 3 16.7
Tissue invasion L0, V0, Pn0 26 27.7 3 16.7 2 11.1 (0.733)
L1, V1 or Pn1 20 21.3 5 27.8 7 38.9
No neck dissection 48 51.1 10 55.6 9 50,0 (1.000)
Shows the patient and tumor characteristics for the total group, study group receiving the cetuximab-taxane schema and the matched pair control group that
potentially influence prognosis. Differences between the study group and the control group were analyzed by *chi-square test and Mann–Whitney U test
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To assess the toxicity of the treatment it has to be
considered, that many patients got tracheostomy, feeding
tube and central venous access device preventively to
manage possible complications like swelling, bleeding or
pain related dysphagia (Additional file 1: Table S1).
Subgroup analysis
We checked for persisting survival advantage by adjusting
the data to ‘age at onset of recurrence disease’ (p = 0,006).
Comparing the patients of the study group who were
younger than 60 years to those of the control group, we
Table 2 Treatment characteristics
Total group (n = 94) Study group (n = 18) Control group (n = 18) p-values*
n % value (range) n % value (range) n % value (range)
Surgical treatment Total 88 93.6 17 94.4 15 83.3 (0.279)
Local resection 78 83.0 14 77.7 14 77.7 (0.397)
Neck dissection 10 10.6 3 16.7 1 5.6 (0.790)
Brachytherapy Total dose (Gy) 25.9 (10–35) 27.0 (15–35) 27.1 (20–30) (0.696)
Single dose (Gy) 2.5 (2.5-4.5) 2.5 (2.5-3.0) 2.5 (2.5-2.5) (0.791)
Fractions 10.2 (4–14) 10.6 (6–14) 10.8 (8–12) (0.938)
Radiation days 6.3 (1–11) 7.1 (4–9) 6.6 (3–9) (0.202)
V100 (ml) 50.0 (3.6-149.5) 61.9 (22.3-149.5) 46.4 (4.0-111.1) (0.291)
V150 (ml) 19.1 (1.6-65.3) 23.1 (7.1-55.2) 17.0 (2.0-37.3) (0.347)
DNR 0.37 (0.32-0.56) 0.35 (0.28-0.46) 0.40 (0.29-0.56) (0.168)
Adjuvant treatment EBRT 24 25.5 4 22.2 3 16.7 (0.557)
Radiation dose (Gy) 48.7 (30–60) 50.1 (50.0-50.4) 35.8 (30–45) (0.887)
Chemotherapy (total) 15 16.0 18 100 2 11.1 (0.000)
Chemotherapy (only platinum
derivatives)
5 5.3 2 11.1 - -
Gives an overview of the performed treatment modalities. The ‘Cetuximab-Taxane Recurrency Scheme’ combines salvage surgery (SS), Brachytherapy (BT) and
adjuvant chemoprotocol in regard to previous external radiation (EBRT), previous chemotherapy (CTx). To exhaust chances an external boost was added whenever
reasonable. Differences between the study group and the control group were analyzed by *chi-square test and Mann–Whitney U test
Fig. 3 Impact of the cetuximab-taxane recurrency scheme on DFS and OS. a displays the disease-free survival (DFS) and b the overall survival (OS) of the
study group (magenta) and the matched pair control group (blue). DFS enhanced about 4.8 months (p= 0.13) and OS about 8.7 months (p= 0.023)
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still observed lower mortality rates and improved OS in
the study group. By contrast, comparing the patients older
than 60 years, they did not improve in OS, although still
showing lower mortality rates. Adjusting to ‘previous re-
currence free survival’ (p = 0,003) was not possible as all
patients of the control group solely had late recurrences.
We also examined the impact of further variables on
the observed survival benefit. Chua et al. implemented a
scoring system for recurrent nasopharyngeal cancer, that
predict re-recurrence by age at diagnosis, period be-
tween radiation and recurrence, T-stage or tumor vol-
ume and number of previous recurrences [9]. We
stratified the study group and the remaining total group
into intermediate (study groupps2, remaining groupps2)
and bad prognosis (study groupps3, remaining groupps3).
To prove the impact of the cetuximab-taxane scheme,
unaffected by prognostic score we compared these
groups at the same prognostic level. However still
showing improved survival, significance could not be
demonstrated, neither in patients with intermediate (p =
0.4), nor with bad prognosis (p = 0.08) (Fig. 4).
Discussion
Treatment regimen
The treatment of recurrent HNSCC is limited by radi-
ation tissue dose, chemotherapy tissue damage, surgical
limits and the patients’ performance status. Whenever
feasible, salvage surgery is the method of choice with
curative intent. Postoperative re-irradiation is expected
to increase LC in patients at high risk for local recur-
rence. However, advantages in OS could not be reported
due to accelerated toxicities [20, 21].
A multimodal therapy regimen, containing several
tools in anti-tumor treatment, could help to reduce spe-
cific toxicity of one treatment but could increase overall
destabilization of cancer cells. Recurrent tumor disease
Table 3 Treatment related toxicities
Total group Study group Control group Salvage surgery Salvage surgery
plus BT
BT in palliation Cetuximab Paclitaxel
% (n = 94) (n = 18) (n = 18)
Overall acute and chronic side effects:
CTC overall 26.6 44.4 33.3 36-39 (III,IV,V) 7-23 (III,IV) 13-35 (II,III) 15-41 (III-IV)
CTC I 6.4 16.7 5.6
CTC II 10.6 16.7 16.7
CTC III 9.6 11.1 11.1
LENT-SOMA overall 14.9 27.8 11.1 7-23 (III,IV) 7-33 (II,III)
LENT-SOMA I 3.2 5.6 5.6
LENT-SOMA II 7.4 16.7 –
LENT-SOMA III 4.3 5.6 5.6
Acute and chronic side effects in detail:
Mucositis 5.4 11.1 5.6 10 (III) 60 (I,II) 8-56 (III,IV) 17-35 (III,IV)
Lymph edema 10.6 16.7 (II,III) 11.1 21
Pain – – – 20 6
Dysphagia 6.4 22.2 – 53-58 (III) 32-39 (II,III) 4-16 26 (II,III) 15
Bleeding 3.2 – 16.7 1-3 (IV,V) 3-14 (II,III,IV) 3-7 (III) 8 (II,II) 14 (III)
Woundheeling disorder 10.6 (II,III) 16.7 (II,III) 5.6 (II,III) 12-17 15-17 (II,III) 4 (III) 11-23 (II,IV)
Soft tissue necrosis – – – 7 (III) 7-28 (II,III)
Osteoradionecrosis – – – 4 (III,IV) 1-17 (II,III)
Fibrosis 2.1 5.6 – 7-29 (II,III) 2-7 (II,III)
Skin reaction 3.1 11.1 (III,IV) 9-16 (III,IV) 12
Infusion reaction 1.1 5.5 (III) 2-22 (III,IV)
Neutropenia 1.1 5.6 (IV) 8 (III,IV) 14-75 (IV)
Renal failure – – 7 (III,IV)
Neuropathy – 4-26 (II,III,IV) 7 (III) 4 7 (III,IV)
Shows the toxicity profile of the study group compared to the total group, the control group and to literature. Other studies treating recurrent HNSCC by salvage
surgery [34–36], salvage surgery combined with Brachytherapy (BT) [32, 42–44], single BT in palliation [24, 37, 38, 42, 43, 45, 46] or studies that used
Cetuximab [1, 11, 47–52] within their regime were listed using the CTC (common toxicity criteria) and LENT (Late Effects Normal Tissue)-SOMA-classifications. The toxicity
levels the percentage values from literature refer to were put in brackets
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often shows higher radiation resistance and higher ex-
pression of the epidermal growth factor receptor (EGFR)
[22]. Adding the monoclonal antibody cetuximab to the
second-line regimen is one option to reduce radio- or
chemotherapy resistance.
In well selected patients re-irradiation, administered
either with or without concurrent systemic therapy, is
feasible [20]. Especially targeted radiation like intensity-
modulated radiation therapy (IMRT), predicts better LC
and OS compared to conventional techniques [23].
Re-irradiation with HDR-BT shows similar encouraging
results, with an acceptable late complication rate of 16 %
[24]. BT is known to be a safe alternative of re-
irradiation compared to EBRT. Due to 3D conformal
Fig. 4 Subgroup analysis. a and b demonstrate the impact of Chua’s prognostic score on the overall survival of patients with intermediate and
bad prognosis in the study group (p = 0.3) and the remaining group (p = 0.003). c and d illustrate the impact of the cetuximab-taxane scheme
unaffected by the prognostic score. It shows improved survival, but significance could not be demonstrated, neither in patients with intermediate
(p = 0.4) nor with bad prognosis (p = 0.08)
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and individual optimized treatment planning, treatment
related side effects can be kept low. The steep dose-
falloff in adjacent tissues spares normal tissue and re-
duces radiation toxicity [24]. So BT became a useful
complement in a multimodal tumor therapy.
Also stereotactic radiation therapy (SRT) has shown
to be a reasonable treatment option in recurrent
HNSCC and was combined with Cetuximab in palli-
ation, yet [25, 26]. But BT showed better local control
and lower toxicity rates than SRT [27]. SRT gives a
homogeneous dose distribution, while BT has an in-
homogeneous dose distribution. This means that the
maximal dose of the SRT applied homogeneous in the
target volume is equivalent to the calculated minimal
dose applied by BT. Next to the applicator BT can
reach dose levels up to 400 percent of this minimal
dose. In addition the total irradiated volume is smaller
in BT. This leads to less complications like soft tissue
necrosis, also when combined with concomitant
chemotherapy [28, 29].
Patients not suitable for salvage surgery can be se-
lected for BT combined with simultaneous chemother-
apy as an effective and safe option for curative therapy
as well [30].
The best in-field control rates in advanced tumors
were obtained, when BT was combined with radical
surgical excision and plastic reconstruction, using vascu-
larized myocutaneous flaps [31, 32]. Tumor debulking
diminishes hypoxic radiation resistant tissue and reduces
the target volume [33]. But only a minority achieves
long-term survival, because of the high risk of systemic
relapse. Especially younger patients, having a disease free
interval after receiving definitive therapy or a small re-
current tumor that can obtain negative surgical margins
and patients without recurrent neck disease benefit from
this treatment [34].
The cetuximab-taxane recurrency scheme combines
these strategies. Thereby we enhanced OS to 14.8 months
and RFS to 8.7 months. So there is evidence for an addi-
tive effect.
Early and late toxicities
Acute and late toxicities must be taken into account, to
value the eligibility of this new regimen as each part of
the treatment can cause adverse effects.
First of all, patients are at risk to suffer from transient
or permanent perioperative consequences concerning
oral intake, speech or breathing, especially in case of sal-
vage surgery. Goodwin et al. reported a rate of 27 % of
all perioperative severe complications and a mortality
rate of 5.2 %. Frequently problems are cardiopulmonary
(4.5 %), bleeding (2.7 %) and wound healing disorders
(infection 4.5 %, necrosis 1.8-8.3 % or fistula 5.5-8.3 %)
[35, 36].
Secondly, early complications as skin reactions (up to
60 %), pain (20 %) or dysphagia (8-16 %) and late com-
plications as soft tissue necrosis (15-28 %), osteoradione-
crosis (0.6-17 %) or chronic woundhealing disorders
(3 %) are associated with BT. Although severe complica-
tions are rare, carotid blowout is feared especially in pre-
vious irradiated tissues [37, 38].
Adding chemotherapy with cetuximab and paclitaxel
adds to toxicity. Paclitaxel can lead to myelosuppression,
e.g. neutropenia (14 to 75 %), hypersensitivity reaction
(2 %), peripheral neuropathy (7 %), mucositis (3 %) and
alopecia. Cetuximab is known to cause acute toxicities,
like acneiform rush (9-13 %), transfusion reaction (3 %)
and disturbance of the water- and salt metabolism.
Nevertheless Cetuximab did not show to raise radiation
toxicity and is usually well tolerated [1]. Curran et al.
showed that mucositis, xerostomia, dysphagia and
weight loss did not increase and performance status did
not deteriorate [39].
Despite combining these therapy modalities in our in-
vestigation, therapy related acute or late toxicities more
than grade III did not increase in the study group, nei-
ther in comparison to the matched pair control group,
nor to literature (Table 3).
Limitations of the study
As the current investigation is based on retrospectively
collected data, the control group had to be built by
matched pair analysis. Due to the small number of pa-
tients, the power of this study and the validity of sub-
group analysis are limited. This is why we would rather
speak of a tendency, although we have seen statistical
significance.
Small groups lead to difficulties especially in the
matching process. We had to decide for some major
prognosis factors. So there were differences in the distri-
bution of some factors e.g. the tumor grading. The
difficulty in recruiting patients is based on variability of
HNSCC recurrences, performance status and compli-
ance of the patients and availability of departments
offering BT for HNSCC. Nevertheless, the investigated
collective has a realistic broad spectrum of entities and
additional treatments.
Prognostic factors
Specifically the influence of prognostic factors cannot be
completely excluded although we used multivariate ana-
lysis and subsequently subgroup analysis to confirm our
data.
The variety of different factors and scoring systems
makes it difficult to figure out which are the most im-
portant factors. Besides clinical and histological fac-
tors, the metabolism of the cancer cell will be an
important focus in the future. High expression of
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EGFR, as well as negative human papillomavirus
(HPV) 16 status, are associated with decreased OS [1].
In this context the authors observed a 13-fold in-
creased risk developing local recurrence [40, 41]. Po-
tentially, accurate knowledge of tumor biology, will
not only improve predictive power, but also assists to
individual treatment planning.
Conclusion
The ‘cetuximab-taxane recurrency scheme’ seems to
be a valuable complement to the multimodal treat-
ment, which improves OS with tolerable toxicity.
Based on the outcome of this investigation, our insti-
tution is currently re-evaluating the internal standard
treatment regimen for patients with recurrent
HNSCC, failing first-line-therapy. The initial promis-
ing clinical data provide a good argument to establish
this schedule in other medical centers. This justifies a
need for prospective randomized clinical trials of a
sufficient power. It should be mentioned, that when
planning new investigations it is necessary to create a
solid base for comparability of the different patient
collectives. Therefore an adjusted and generally ac-
cepted scoring system has to be developed, that in-
volves molecular as well as clinical prognostic issues,
so one can identify those who will benefit most from
escalating the treatment.
Additional file
Additional file 1: Table S1. Preventive complication management.
Table S1 shows the distribution of patients having tracheostomy, central
venous access device (CVAD) and feeding tube including feeding status
at discharge from hospital. (DOCX 36 kb)
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